• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Antibiotics for Inflammation Research
You are here: Product Lines > Cancer > Antibiotics for Inflammation Research
Toolbar - View Selection
 
Items 6 of 6
ALX-350-334 Revised 03-Apr-08
Ascochlorin
Add to Clipboard
SYNONYMS LL-Z 1272 γ
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antitumor Antibiotics
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-334-MC05   0.5 mg 320.00 USD Add To Cart
Product Specification
FORMULA: C23H29ClO4
MW: 404.9
CAS NUMBER: 26166-39-2
RTECS: VH3707560
SOURCE/HOST: Isolated from Acremonium sp. MST-FP1890.
PURITY: ≥95% (HPLC)
APPEARANCE: White to light grey powder.
SOLUBILITY: Soluble in 100% ethanol, methanol, dimethyl formamide or DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.
HAZARD: TOXIC.

Product Description
Antitumor antibiotic. Shows antiviral activity. Inhibitor or matrix metalloproteinase 9 (MMP-9). Reduces the inflammatory response to TNF-α in rat vascular smooth muscle cells. May be useful as an antiatherogenic agent.
Product Specific Literature References
Ascochlorin, a new antibiotic, found by the paper-disc agar-diffusion method. I. Isolation, biological and chemical properties of ascochlorin. (Studies on antiviral and antitumor antibiotics. I): G. Tamura, et al.; J. Antibiot. (Tokyo) 21, 539 (1968) Abstract
Ascochlorin derivatives as ligands for nuclear hormone receptors: M. Togashi, et al.; J. Med. Chem. 46, 4113 (2003) Abstract
Ascochlorin inhibits matrix metalloproteinase-9 expression by suppressing activator protein-1-mediated gene expression through the ERK1/2 signaling pathway: inhibitory effects of ascochlorin on the invasion of renal carcinoma cells: S. Hong, et al.; J. Biol. Chem. 280, 25202 (2005) Abstract; Full Text
Selective cytotoxicity of ascochlorin in ER-negative human breast cancer cell lines: K. Sakaguchi, et al.; BBRC 329, 46 (2005) Abstract
Ascochlorin suppresses oxLDL-induced MMP-9 expression by inhibiting the MEK/ERK signaling pathway in human THP-1 macrophages: J.H. Kang, et al.; J. Cell. Biochem. 102, 506 (2007) Abstract
Further Categories Containing This Product:
MMP Inhibitors • Antibiotics for Cytoskeletal Research • Antibiotics for Inflammation Research • Antibiotics - Antiviral/Anti-HIV
 
 
ALX-350-254 Revised 10-Mar-08
Epoxomicin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Proteasome/Ubiquitin Modulators
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-254-C050   50 µg 132.00 USD Add To Cart
Product Specification
FORMULA: C28H50N4O7
MW: 554.7
CAS NUMBER: 134381-21-8
MERCK INDEX: 14: 3630
SOURCE/HOST: Synthetic.
PURITY: ≥95% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO (15mg/ml); insoluble in water.
ACTIVITY: kobs/[I] = 25’000M-1s-1 versus 20S proteasome.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles. Protect from light.
IDENTITY: Identity determined by 1H-NMR.

Product Description
Cell permeable, potent and selective proteasome inhibitor originally isolated from Actinomycetes strain based on its potent in vivo antitumor activity. More potent inhibitor of the chymotrypsin-like activity of the proteasome than lactacystin. Effectively inhibits NF-κB activation in vitro and potently blocks inflammation in vivo in the mouse ear edema assay.
Product Specific Literature References
Epoxomicin, a new antitumor agent of microbial origin: M. Hanada, et al.; J. Antibiot. (Tokyo) 45, 1746 (1992) Abstract
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency: K.B. Kim, et al.; Bioorg. Med. Chem. Lett. 9, 3335 (1999) Abstract
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity: L. Meng, et al.; PNAS 96, 10403 (1999) Abstract
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology: N. Sin, et al.; Bioorg. Med. Chem. Lett. 9, 2283 (1999) Abstract
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses: K. Schwarz, et al.; J. Immunol. 164, 6147 (2000) Abstract
Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431: K. Ohkawa, et al.; Int. J. Oncol. 24, 425 (2004) Abstract
Further Categories Containing This Product:
Antitumor Agents (Enzyme Inhibitors) • Proteasome/Related Products • NF-kB Pathway Inhibitors • Antitumor Antibiotics • Antibiotics for Inflammation Research • Antibiotics - NF-kB Inhibitors • Anti-inflammatory Agents Other Products
 
 
ALX-380-274 Revised 21-May-08
Erythromycin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics for Inflammation Research
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-274-G005   5 g 40.00 USD Add To Cart
Product Specification
FORMULA: C37H67NO13
MW: 733.9
CAS NUMBER: 114-07-8
MERCK INDEX: 14: 3681
RTECS: KF4375000
SOURCE/HOST: Isolated from Streptomyces erythreus.
PURITY: ≥85% (Assay on dry basis)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in water (50mg/ml), 100% ethanol or methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HAZARD: HARMFUL.

Product Description
Macrolide antibiotic. Inhibits protein synthesis (elongation) at the transpeptidation step. Binds to the 23S RNA of the 50S ribosomal subunit. Effective against Gram-negative and Gram-positive bacteria.
Product Specific Literature References
Inducible erythromycin resistance in bacteria: B. Weisblum; Br. Med. Bull. 40, 47 (1984) Abstract
Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells: Y. Aoki & P.N. Kao; Antimicrob. Agents Chemother. 43, 2678 (1999) Abstract; Full Text
Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban: J.Q. Tran, et al.; J. Clin. Pharmacol. 39, 513 (1999) Abstract
Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism: T. Tokairin, et al.; Br. J. Clin. Pharmacol. 60, 172 (2005) Abstract; Full Text
Related Products
Further Categories Containing This Product:
NF-kB Pathway Inhibitors • Translation Inhibitors • Anti-inflammatory Agents Other Products
 
 
ALX-380-109 Revised 01-Jul-08
Minocycline . hydrochloride
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics for Angiogenesis Research
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-109-M050   50 mg 30.00 USD Add To Cart
Product Specification
FORMULA: C23H27N3O7 . HCl
MW: 457.5 . 36.5
CAS NUMBER: 13614-98-7
MERCK INDEX: 14: 6202
RTECS: QI7630500
SOURCE/HOST: Semi-synthetic
APPEARANCE: Yellow crystalline solid.
SOLUBILITY: Soluble in water (50mg/ml, warm) or DMSO (7mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HAZARD: IRRITANT.

Product Description
Tetracycline derivative with antimicrobial activity. Inhibitor of angiogenesis, apoptosis and poly(ADP-ribose) polymerase-1 (PARP-1). Anti-inflammatory and neuroprotective.
Product Specific Literature References
Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma: J.L. Frazier, et al.; J. Neurooncol. 64, 203 (2003) Abstract
Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases: J.S. Yao, et al.; Circ. Res. 95, 364 (2004) Abstract
Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria: J. Wang, et al.; J. Biol. Chem. 279, 19948 (2004) Abstract
Minocycline up-regulates BCL-2 levels in mitochondria and attenuates male germ cell apoptosis: M. Castanares, et al.; BBRC 337, 663 (2005) Abstract
Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy: J.K. Krady, et al.; Diabetes 54, 1559 (2005) Abstract
Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations: C.C. Alano, et al.; PNAS 103, 9685 (2006) Abstract
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation: K. Maier, et al.; Neurobiol. Dis. 25, 514 (2007) Abstract
Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration: J.S. Yao, et al.; Neurochem. Int. 50, 524 (2007) Abstract
Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia: Y. Levkovitz, et al.; Brain Res. 1154, 154 (2007) Abstract
Further Categories Containing This Product:
Antibiotics - Apoptosis Inducers & Inhibitors • NOS Inhibitors (NOS Induction & Enzyme Activity) • Antibiotics - Nitric Oxide Pathway Modulators • COX Inhibitors • Antibiotics for Inflammation Research • Neuroactive Agents Other Products • PARP Inhibitors
 
 
ALX-380-294 Revised 15-Apr-08 New product
Nadifloxacin
Add to Clipboard
SYNONYMS 9-Fluoro-6,7-dihydro-8-(4-hydroxypiperidino)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid
Jinofloxacin
OPC-7251
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-294-M250   250 mg 90.00 USD Add To Cart
ALX-380-294-G001   1 g 270.00 USD Add To Cart
Product Specification
FORMULA: C19H21FN2O4
MW: 360.4
CAS NUMBER: 124858-35-1
MERCK INDEX: 14: 6345
PURITY: ≥98% (Assay)
APPEARANCE: White to yellow crystalline solid.
SOLUBILITY: Soluble in DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Fluoroquinolone with broad spectrum activity against Gram-negative and Gram-positive bacteria. Inhibits the generation of O2- and OH radicals by neutrophils. Inhibits the production of inflammtory cytokines.
Product Specific Literature References
Studies on antibacterial agents. I. Synthesis of substituted 6,7-dihydro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acids: H. Ishikawa, et al.; Chem. Pharm. Bull. 37, 2103 (1989) Abstract
Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base: I. Kurokawa, et al.; J. Am. Acad. Dermatol. 25, 674 (1991) Abstract
Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris: K. Vogt, et al.; Eur. J. Clin. Microbiol. Infect. Dis. 11, 943 (1992) Abstract
Effect of nadifloxacin on neutrophil functions: H. Akamatsu, et al.; J. Int. Med. Res. 23, 19 (1995) Abstract
Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus: N. Oizumi, et al.; J. Infect. Chemother. 7, 191 (2001) Abstract
Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections: P. Nenoff, et al.; Chemotherapy 50, 196 (2004) Abstract
Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes: K. Kuwahara, et al.; J. Dermatol. Sci. 38, 47 (2005) Abstract
Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771: M.R. Jacobs & P.C. Appelbaum; Expert Opin. Pharmacother. 7, 1957 (2006) Abstract
Further Categories Containing This Product:
Antibiotics - Topoisomerase Inhibitors • Antibiotics - DNA Replication Inhibitors • Antibiotics for Inflammation Research
 
 
ALX-380-060 Revised 11-Jul-08
Tetracycline . hydrochloride
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Other Antibiotics - DNA Regulation/Transcription
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-060-G005   5 g 20.00 USD Add To Cart
Product Specification
FORMULA: C22H24N2O8 . HCl
MW: 444.5 . 36.5
CAS NUMBER: 64-75-5
MERCK INDEX: 14: 9196
RTECS: QI9100000
APPEARANCE: Yellow solid.
SOLUBILITY: Soluble in water, methanol or 100% ethanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HANDLING: Protect from light and moisture.
HAZARD: IRRITANT.

Product Description
Broad-spectrum antibiotic with anti-inflammatory activity. Blocks bacterial protein synthesis by inhibiting binding of aminoacyl tRNA to A-site of ribosomes. Tetracycline-controlled systems are used to control gene expression on transgenic mice. Marker of bone formation.
Product Specific Literature References
Clinical and laboratory observations of a new antibiotic, tetracycline: M. Finland, et al.; J. Am. Med. Assoc. 154, 561 (1954) Abstract
Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance: I. Chopra & M. Roberts; Microbiol. Mol. Biol. Rev. 65, 232 (2001) Abstract
Tetracyclines: nonantibiotic properties and their clinical implications: A. N. Sapadin & R. Fleischmajer; J. Am. Acad. Dermatol. 54, 258 (2006) Abstract
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide: R. Lindsay, et al.; J. Bone Miner. Res. 21, 366 (2006) Abstract
Tetracycline-controlled genetic switches: R. Sprengel & M. T. Hasan; Handb. Exp. Pharmacol. 178, 49 (2007) Abstract
Anti-inflammatory activity of tetracyclines: G. Webster & J. Q. Del Rosso; Dermatol. Clin. 25, 133 (2007) Abstract
Further Categories Containing This Product:
tRNA/Related Products • Antibiotics for Inflammation Research • Antibiotics - Apoptosis Inducers & Inhibitors • Translation Inhibitors
 
 
© 2008 ALEXIS Corporation, Privacy Policy, Disclaimer, Feedbackanother CS2 website

Catalogs / Brochures

E-Newsletter

 

Shopping Cart [0]

 

Distributors

Online Product Ordering

Clipboard [0]

Your items will be kept only for the duration of your visit.